A phase I, open-label study evaluating the safety, pharmacokinetics, and pharmacodynamic effects on de novo lipogenesis of the acetyl-CoA carboxylase inhibitor GS-0976 in healthy volunteers
Latest Information Update: 10 Dec 2018
Price :
$35 *
At a glance
- Drugs Firsocostat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 17 Nov 2017 New trial record
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases